Stroke prevention in diabetes with glucagon-like peptide-1 receptor agonists: A game-changer?

被引：1

作者：

Katsiki, Niki ^{[1
]}

Fonseca, Vivian ^{[2
]}

机构：

[1] AHEPA Univ Hosp, Div Endocrinol & Metab, Diabet Ctr, Dept Internal Med 1, 1st Stilponos Kyriakidi, Thessaloniki 54621, Greece

[2] Tulane Univ, Sch Med, Deming Dept Med, Sect Endocrinol & Metab, 1430 Tulane Ave, New Orleans, LA 70112 USA

来源：

JOURNAL OF DIABETES AND ITS COMPLICATIONS | 2021年 / 35卷 / 12期

基金：

美国国家卫生研究院;

关键词：

CARDIOVASCULAR OUTCOMES; TYPE-2; MELLITUS; EMPAGLIFLOZIN; PIOGLITAZONE; EVENTS; RISK; BAD;

D O I：

10.1016/j.jdiacomp.2021.108075

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：3

共 35 条

[1]

[Anonymous], 2021, DIABETES CARE, V44, pS1, DOI DOI 10.2337/dc19-SINT01

[2] Glucagon-Like Peptide-1 Receptor Agonists and Prevention of Stroke Systematic Review of Cardiovascular Outcome Trials With Meta-Analysis [J].

Bellastella, Giuseppe ;

Maiorino, Maria Ida ;

Longo, Miriam ;

Scappaticcio, Lorenzo ;

Chiodini, Paolo ;

Esposito, Katherine ;

Giugliano, Dario .

STROKE, 2020, 51 (02) :666-669

[3] GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE REVIEW OF HOW TO WEIGH THE OPTIONS, SELECT THE RIGHT PATIENTS, AND MAXIMIZE BENEFITS [J].

Blonde, Lawrence ;

Fonseca, Vivian .

ENDOCRINE PRACTICE, 2018, 24 :8-22

[4] Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes [J].

Cannon, Christopher P. ;

Pratley, Richard ;

Dagogo-Jack, Samuel ;

Mancuso, James ;

Huyck, Susan ;

Masiukiewicz, Urszula ;

Charbonnel, Bernard ;

Frederich, Robert ;

Gallo, Silvina ;

Cosentino, Francesco ;

Shih, Weichung J. ;

Gantz, Ira ;

Terra, Steven G. ;

Cherney, David Z. I. ;

McGuire, Darren K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) :1425-1435

[5] Diabetes and Stroke: Epidemiology, Pathophysiology, Pharmaceuticals and Outcomes [J].

Chen, Rong ;

Ovbiagele, Bruce ;

Feng, Wuwei .

AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2016, 351 (04) :380-386

[6] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[7] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial [J].

Gerstein, Hertzel C. ;

Colhoun, Helen M. ;

Dagenais, Gilles R. ;

Diaz, Rafael ;

Lakshmanan, Mark ;

Pais, Prem ;

Probstfield, Jeffrey ;

Riesmeyer, Jeffrey S. ;

Riddle, Matthew C. ;

Ryden, Lars ;

Xavier, Denis ;

Atisso, Charles Messan ;

Dyal, Leanne ;

Hall, Stephanie ;

Rao-Melacini, Purnima ;

Wong, Gloria ;

Avezum, Alvaro ;

Basile, Jan ;

Chung, Namsik ;

Conget, Ignacio ;

Cushman, William C. ;

Franek, Edward ;

Hancu, Nicolae ;

Hanefeld, Markolf ;

Holt, Shaun ;

Jansky, Petr ;

Keltai, Matyas ;

Lanas, Fernando ;

Leiter, Lawrence A. ;

Lopez-Jaramillo, Patricio ;

Cardona Munoz, Ernesto German ;

Pirags, Valdis ;

Pogosova, Nana ;

Raubenheimer, Peter J. ;

Shaw, Jonathan E. ;

Sheu, Wayne H-H ;

Temelkova-Kurktschiev, Theodora .

LANCET, 2019, 394 (10193) :121-130

[8] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial [J].

Hernandez, Adrian F. ;

Green, Jennifer B. ;

Janmohamed, Salim ;

D'Agostino, Ralph B., Sr. ;

Granger, Christopher B. ;

Jones, Nigel P. ;

Leiter, Lawrence A. ;

Rosenberg, Anne E. ;

Sigmon, Kristina N. ;

Somerville, Matthew C. ;

Thorpe, Karl M. ;

McMurray, John J. V. ;

Del Prato, Stefano .

LANCET, 2018, 392 (10157) :1519-1529

[9] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes [J].

Holman, Rury R. ;

Bethel, M. Angelyn ;

Mentz, Robert J. ;

Thompson, Vivian P. ;

Lokhnygina, Yuliya ;

Buse, John B. ;

Chan, Juliana C. ;

Choi, Jasmine ;

Gustavson, Stephanie M. ;

Iqbal, Nayyar ;

Maggioni, Aldo P. ;

Marso, Steven P. ;

Ohman, Peter ;

Pagidipati, Neha J. ;

Poulter, Neil ;

Ramachandran, Ambady ;

Zinman, Bernard ;

Hernandez, Adrian F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13) :1228-1239

[10] Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes [J].

Husain, Mansoor ;

Birkenfeld, Andreas L. ;

Donsmark, Morten ;

Dungan, Kathleen ;

Eliaschewitz, Freddy G. ;

Franco, Denise R. ;

Jeppesen, Ole K. ;

Lingvay, Ildiko ;

Mosenzon, Ofri ;

Pedersen, Sue D. ;

Tack, Cees J. ;

Thomsen, Mette ;

Vilsboll, Tina ;

Warren, Mark L. ;

Bain, Stephen C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (09) :841-851

← 1 2 3 4 →